Assembly Biosciences, Inc. (ASMB): Price and Financial Metrics

Assembly Biosciences, Inc. (ASMB): $1.04

-0.03 (-2.80%)

POWR Rating

Component Grades













ASMB Stock Price Chart Interactive Chart >

Price chart for ASMB

ASMB Price/Volume Stats

Current price $1.04 52-week high $2.42
Prev. close $1.07 52-week low $0.82
Day low $1.01 Volume 111,100
Day high $1.06 Avg. volume 258,198
50-day MA $1.45 Dividend yield N/A
200-day MA $1.67 Market Cap 54.02M

Assembly Biosciences, Inc. (ASMB) Company Bio

Assembly Biosciences develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus and C. difficile-associated infections. The company was founded in 2005 and is based in New York, New York.

ASMB Latest News Stream

Event/Time News Detail
Loading, please wait...

ASMB Latest Social Stream

Loading social stream, please wait...

View Full ASMB Social Stream

Latest ASMB News From Around the Web

Below are the latest news stories about ASSEMBLY BIOSCIENCES INC that investors may wish to consider to help them evaluate ASMB as an investment opportunity.

Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-e

Yahoo | February 15, 2023

Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs

Assembly Biosciences Inc (NASDAQ: ASMB) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334). For the Phase 1b trial of 3733, the dose selected for the first cohort was 50 mg. A dose of 100 mg has been selected for the third cohort, for which dosing is ongoing, with initial data anticipated in Q1 of 2023. Related: Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection. In the 50 m

Yahoo | December 19, 2022

Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334

In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in plasma HBV DNAInitial ABI-4334 Phase 1a single-dose 30 mg cohort demonstrated pharmacokinetic profile supportive of once-daily oral dosing and provides early indication that ABI-4334's very high potency seen preclinically can be accessed clinicallyNo serious adverse events or significa

Yahoo | December 19, 2022

Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334

Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that the first subject has been dosed in the Phase 1a trial of its investigational core inhibitor ABI-4334 (4334). 4334 is an investigat

Yahoo | November 14, 2022

Analysts Offer Insights on Healthcare Companies: Emergent Biosolutions (EBS), Inovio Pharmaceuticals (INO) and Assembly Biosciences (ASMB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Emergent Biosolutions (EBS – Research Report), Inovio Pharmaceuticals (INO – Research Report) and Assembly Biosciences (ASMB – Research Report). Emergent Biosolutions (EBS) Chardan Capital analyst Keay Nakae reiterated a Buy rating on Emergent Biosolutions today and set a price target of $55.00. The company's shares closed last Tuesday at $19.73, close to its 52-week low of $18.00. According to TipRanks.

Howard Kim on TipRanks | November 9, 2022

Read More 'ASMB' Stories Here

ASMB Price Returns

1-mo -22.96%
3-mo N/A
6-mo -37.35%
1-year -52.51%
3-year -93.09%
5-year -98.10%
YTD -20.00%
2022 -44.21%
2021 -61.49%
2020 -70.43%
2019 -9.55%
2018 -50.01%

Continue Researching ASMB

Want to see what other sources are saying about Assembly Biosciences Inc's financials and stock price? Try the links below:

Assembly Biosciences Inc (ASMB) Stock Price | Nasdaq
Assembly Biosciences Inc (ASMB) Stock Quote, History and News - Yahoo Finance
Assembly Biosciences Inc (ASMB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7381 seconds.